SEARCH

SEARCH BY CITATION

References

  • Abayli, B., A. Canataroglu, and H. Akkiz. 2003. Serum profile of T helper 1 and T helper 2 cytokines in patients with chronic hepatitis C virus infection. Turk. J. Gastroenterol. 14:711.
  • Akcam, F. Z., A. Tigli, O. Kaya, M. Ciris, and H. Vural. 2012. Cytokine levels and histopathology in chronic hepatitis B and chronic hepatitis C. J. Interferon Cytokine Res. 32:570574.
  • Alexander, G. M., B. L. Peterlin, M. J. Perreault, J. R. Grothusen, and R. J. Schwartzman. 2012. Changes in plasma cytokines and their soluble receptors in complex regional pain syndrome. J. Pain 13:1020.
  • American Psychiatric Association. 2000. Diagnostic and statistical manual for mental disorders. 4th ed. American Psychiatric Association, Washington, DC.
  • Anderson, G., M. Berk, O. Dean, S. Moylan, and M. Maes. 2013. Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications. CNS Drugs. [Epub ahead of print].
  • Argyropoulos, S. V., G. B. Ploubidis, T. S. Wright, M. E. Palm, S. D. Hood, J. R. Nash, et al. 2007. Development and validation of the Generalized Anxiety Disorder Inventory (GADI). J. Psychopharmacol. 21:145152.
  • Arnett, S. V., and I. A. Clark. 2012. Inflammatory fatigue and sickness behaviour—lessons for the diagnosis and management of chronic fatigue syndrome. J. Affect. Disord. 141:130142.
  • Arnold, S. E., S. X. Xie, Y. Y. Leung, L. S. Wang, M. A. Kling, X. Han, et al. 2012. Plasma biomarkers of depressive symptoms in older adults. Transl. Psychiatry 2:e65.
  • Beck, A. T. 1996. Beck Depression Inventory. 2nd ed. The Psychological Corporation, San Antonio, TX.
  • Breen, E. C., S. M. Reynolds, C. Cox, L. P. Jacobson, L. Magpantay, C. B. Mulder, et al. 2011. Multisite comparison of high-sensitivity multiplex cytokine assays. Clin. Vaccine Immunol. 18:12291242.
  • Britschgi, M. and T. Wyss-Coray. 2009. Blood protein signature for the early diagnosis of Alzheimer disease. Arch. Neurol. 66:161165.
  • Bruno, C. M., C. Sciacca, D. Cilio, G. Bertino, A. E. Marchese, G. Politi, et al. 2005. Circulating adhesion molecules in patients with virus-related chronic diseases of the liver. World J. Gastroenterol. 11:45664569.
  • Camargo, J. F., P. Quinones, S. Mummidi, S. Srinivas, A. A. Gaitan, K. Begum, et al. 2009. CCR5 expression levels influence NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte activation. J. Immunol. 182:171182.
  • Capuron, L., and A. H. Miller. 2011. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol. Ther. 130:226238.
  • Chen, B., D. Dowlatshahi, G. M. MacQueen, J. F. Wang, and L. T. Young. 2001. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol. Psychiatry 50:260265.
  • Chen, Q. R., Y. K. Song, L. R. Yu, J. S. Wei, J. Y. Chung, S. M. Hewitt, et al. 2010. Global genomic and proteomic analysis identifies biological pathways related to high-risk neuroblastoma. J. Proteome Res. 9:373382.
  • Cleeland, C. S., and K. M. Ryan. 1994. Pain assessment: global use of the Brief Pain Inventory. Ann. Acad. Med. Singapore 23:129138.
  • Codices, V., C. Martins, C. Novo, B. de Sousa, A. Lopes, M. Borrego, et al. 2012. Dynamics of cytokines and immunoglobulins serum profiles in primary and secondary Cryptosporidium parvum infection: usefulness of Luminex® xMAP technology. Exp. Parasitol. 133:106113.
  • Corona, A. W., A. M. Fenn, and J. P. Godbout. 2012. Cognitive and behavioral consequences of impaired immunoregulation in aging. J. Neuroimmune Pharmacol. 7:723.
  • Cortese, G. P., R. M. Barrientos, S. F. Maier, and S. L. Patterson. 2011. Aging and a peripheral immune challenge interact to reduce mature brain-derived neurotrophic factor and activation of TrkB, PLCgamma1, and ERK in hippocampal synaptoneurosomes. J. Neurosci. 31:42744279.
  • Dan, A. A., L. M. Martin, C. Crone, J. P. Ong, D. W. Farmer, T. Wise, et al. 2006. Depression, anemia and health-related quality of life in chronic hepatitis C. J. Hepatol. 44:491498.
  • Dantzer, R. and K. W. Kelley. 2007. Twenty years of research on cytokine-induced sickness behavior. Brain Behav. Immun. 21:153160.
  • De Masi, R., D. Vergara, S. Pasca, R. Acierno, M. Greco, L. Spagnolo, et al. 2009. PBMCs protein expression profile in relapsing IFN-treated multiple sclerosis: a pilot study on relation to clinical findings and brain atrophy. J. Neuroimmunol. 210:8086.
  • Diniz, B. S., A. L. Teixeira, L. L. Talib, V. A. Mendonca, W. F. Gattaz, and O. V. Forlenza. 2010. Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression. J. Psychiatr. Res. 44:917920.
  • Domenici, E., D. R. Wille, F. Tozzi, I. Prokopenko, S. Miller, A. McKeown, et al. 2010. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case–control collections. PLoS ONE 5:e9166.
  • Dowlati, Y., N. Herrmann, W. Swardfager, H. Liu, L. Sham, E. K. Reim, et al. 2010. A meta-analysis of cytokines in major depression. Biol. Psychiatry 67:446457.
  • Duivis, H. E., N. Vogelzangs, N. Kupper, P. de Jonge, and B. W. Penninx. 2013. Differential association of somatic and cognitive symptoms of depression and anxiety with inflammation: findings from the Netherlands Study of Depression and Anxiety (NESDA). Psychoneuroendocrinology 38:15731585.
  • Dwight, M. M., K. V. Kowdley, J. E. Russo, P. S. Ciechanowski, A. M. Larson, and W. J. Katon. 2000. Depression, fatigue, and functional disability in patients with chronic hepatitis C. J. Psychosom. Res. 49:311317.
  • Egan, M. F., M. Kojima, J. H. Callicott, T. E. Goldberg, B. S. Kolachana, A. Bertolino, et al. 2003. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112:257269.
  • El-Gohary, A. M., N. A. Fawaz, H. M. Hassoba, A. Serwah, and M. Ali. 2004. Soluble ICAM-1 in patients with chronic hepatitis C infection: a prognostic marker of disease activity. Egypt. J. Immunol. 11:109119.
  • Falasca, K., C. Ucciferri, M. Dalessandro, P. Zingariello, P. Mancino, C. Petrarca, et al. 2006. Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann. Clin. Lab. Sci. 36:144150.
  • Ferentinos, P., V. Kontaxakis, B. Havaki-Kontaxaki, D. Dikeos, and L. Lykouras. 2011. Psychometric evaluation of the Fatigue Severity Scale in patients with major depression. Qual. Life Res. 20:457465.
  • Fireman, M., D. W. Indest, A. Blackwell, A. J. Whitehead, and P. Hauser. 2005. Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care. Clin. Infect. Dis. 40:S286S291.
  • Florholmen, J., M. G. Kristiansen, S. E. Steigen, S. W. Sørbye, E. J. Paulssen, J. M. Kvamme, et al. 2011. A rapid chemokine response of macrophage inflammatory protein (MIP)-1α, MIP-1β and the regulated on activation, normal T expressed and secreted chemokine is associated with a sustained virological response in the treatment of chronic hepatitis C. Clin. Microbiol. Infect. 17:204209.
  • Freeman, W. M., A. C. Salzberg, S. W. Gonzales, K. A. Grant, and K. E. Vrana. 2010. Classification of alcohol abuse by plasma protein biomarkers. Biol. Psychiatry 68:219222.
  • Golden, J., A. M. O'Dwyer, and R. M. Conroy. 2005. Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen. Hosp. Psychiatry 27:431438.
  • Gomez Ravetti, M. and P. Moscato. 2008. Identification of a 5-protein biomarker molecular signature for predicting Alzheimer's disease. PLoS ONE 3:e3111.
  • Graham, C. S., A. Wells, E. M. Edwards, T. Herren, S. Tumilty, S. O. Stuver, et al. 2007. Effect of exposure to injection drugs or alcohol on antigen-specific immune responses in HIV and hepatitis C virus coinfection. J. Infect. Dis. 195:847856.
  • Gran, B., G. X. Zhang, and A. Rostami. 2004. Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory demyelination. Crit. Rev. Immunol. 24:111128.
  • Grassi-Oliveira, R., E. Brietzke, J. C. Pezzi, R. P. Lopes, A. L. Teixeira, and M. E. Bauer. 2009. Increased soluble tumor necrosis factor-alpha receptors in patients with major depressive disorder. Psychiatry Clin. Neurosci. 63:202208.
  • Grungreiff, K., T. Hebell, K. Gutensohn, A. Reinhold, and D. Reinhold. 2009. Plasma concentrations of zinc, copper, interleukin-6 and interferon-gamma, and plasma dipeptidyl peptidase IV activity in chronic hepatitis C. Mol. Med. Rep. 2:6368.
  • Hashimoto, K. 2010. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin. Neurosci. 64:341357.
  • Helaly, G. F., and L. A., Abou Shamaa. 2006. Influence of hepatitis C virus infection on circulating levels of sICAM-1 and VEGF in patients with hepatitis C and hepatocellular carcinoma (HCC) and their role in enhancing detection of HCC. Egypt. J. Immunol. 13:2738.
  • Hestad, K. A., S. Tonseth, C. D. Stoen, T. Ueland, and P. Aukrust. 2003. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J. ECT 19:183188.
  • Hilsabeck, R. C., G. M. Anstead, A. L. Webb, A. Hoyumpa, P. Ingmundson, S. Holliday, et al. 2010. Cognitive efficiency is associated with endogenous cytokine levels in patients with chronic hepatitis C. J. Neuroimmunol. 221:5361.
  • Himmerich, H., S. Fulda, J. Linseisen, H. Seiler, G. Wolfram, S. Himmerich, et al. 2008. Depression, comorbidities and the TNF-alpha system. Eur. Psychiatry 23:421429.
  • Ho, A. S., C. C. Cheng, S. C. Lee, M. L. Liu, J. Y. Lee, W. M. Wang, et al. 2010. Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI. J. Biomed. Sci. 17:58.
  • Hoge, E. A., K. Brandstetter, S. Moshier, M. H. Pollack, K. K. Wong, and N. M. Simon. 2009. Broad spectrum of cytokine abnormalities in panic disorder and posttraumatic stress disorder. Depress. Anxiety 26:447455.
  • Hou, R., and D. S. Baldwin. 2012. A neuroimmunological perspective on anxiety disorders. Hum. Psychopharmacol. 27:614.
  • Howren, M. B., D. M. Lamkin, and J. Suls. 2009. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 71:171186.
  • Hu, W. T., A. Chen-Plotkin, S. E. Arnold, M. Grossman, C. M. Clark, L. M. Shaw, et al. 2010. Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol. 119:669678.
  • Jones, K. A., and C. Thomsen. 2013. The role of the innate immune system in psychiatric disorders. Mol. Cell. Neurosci. 53:5262.
  • Keller, S., C. M. Bann, S. L. Dodd, J. Schein, T. R. Mendoza, and C. S. Cleeland. 2004. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin. J. Pain 20:309318.
  • Kikly, K., L. Liu, S. Na, and J. D. Sedgwick. 2006. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr. Opin. Immunol. 18:670675.
  • Kleinman, L., M. W. Zodet, Z. Hakim, J. Aledort, C. Barker, K. Chan, et al. 2000. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual. Life Res. 9:499508.
  • Krügel, U., J. Fischer, S. Radicke, U. Sack, and H. Himmerich. 2013. Antidepressant effects of TNF-α blockade in an animal model of depression. J. Psychiatr. Res. 47:611616.
  • Krupp, L. B., N. G. LaRocca, J. Muir-Nash, and A. D. Steinberg. 1989. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch. Neurol. 46:11211123.
  • Kubera, M., A. H. Lin, G. Kenis, E. Bosmans, D. van Bockstaele, and M. Maes. 2001. Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J. Clin. Psychopharmacol. 21:199206.
  • Kurita, M., S. Nishino, M. Kato, Y. Numata, and T. Sato. 2012. Plasma brain-derived neurotrophic factor levels predict the clinical outcome of depression treatment in a naturalistic study. PLoS ONE 7:e39212.
  • Langowski, J. L., X. Zhang, L. Wu, J. D. Mattson, T. Chen, K. Smith, et al. 2006. IL-23 promotes tumour incidence and growth. Nature 442:461465.
  • ŁApiński, T. W., A. Kot, and D. Prokopowicz. 2002. Concentration of b2-microglobulin and percentage of CD4 lymphocytes in peripheral blood in patients with chronic HCV infection during IFN-a therapy. Med. Sci. Monit. 8:CR538CR542.
  • Larrubia, J. R., S. Benito-Martínez, M. Calvino, E. Sanz-de-Villalobos, and T. Parra-Cid. 2008. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J. Gastroenterol. 14:71497159.
  • Lavanchy, D. 2009. The global burden of hepatitis C. Liver Int. 29:7481.
  • Lee, N. P., L. Chen, M. C. Lin, F. H. Tsang, C. Yeung, R. T. Poon, et al. 2009. Proteomic expression signature distinguishes cancerous and nonmalignant tissues in hepatocellular carcinoma. J. Proteome Res. 8:12931303.
  • Leonard, B., and M. Maes. 2012. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci. Biobehav. Rev. 36:764785.
  • Leroy, V., F. Monier, S. Bottari, C. Trocme, N. Sturm, M. N. Hilleret, et al. 2004. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am. J. Gastroenterol. 99:271279.
    Direct Link:
  • Levine, J., Y. Barak, K. N. Chengappa, A. Rapoport, M. Rebey, and V. Barak. 1999. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 40:171176.
  • Loftis, J. M., and P. Hauser. 2004. The phenomenology and treatment of interferon-induced depression. J. Affect. Disord. 82:175190.
  • Loftis, J. M., M. Huckans, S. Ruimy, D. J. Hinrichs, and P. Hauser. 2008. Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha. Neurosci. Lett. 430:264268.
  • Loftis, J. M., M. Huckans, and B. J. Morasco. 2010. Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies. Neurobiol. Dis. 37:519533.
  • Loftis, J. M., A. L. Patterson, C. J. Wilhelm, H. McNett, B. J. Morasco, M. Huckans, et al. 2013a. Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: a 16-week prospective study. J. Psychosom. Res. 74:5763.
  • Loftis, J. M., C. J. Wilhelm, A. A. Vandenbark, and M. Huckans. 2013b. Partial MHC/neuropeptide: a potential neuroimmune-based treatment for methamphetamine addiction. PLoS ONE 8:e56306.
  • Lotrich, F. E., S. Albusaysi, and R. E. Ferrell. 2012. Brain-derived neurotrophic factor serum levels and genotype: association with depression during interferon-α treatment. Neuropharmacology 38:985995.
  • Maes, M., H. Y. Meltzer, E. Bosmans, R. Bergmans, E. Vandoolaeghe, R. Ranjan, et al. 1995. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. Affect. Disord. 34:301309.
  • Maes, M., C. Song, A. H. Lin, S. Bonaccorso, G. Kenis, R. De Jongh, et al. 1999. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 20:370379.
  • Maes, M., R. Yirmyia, J. Noraberg, S. Brene, J. Hibbeln, G. Perini, et al. 2009. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab. Brain Dis. 24:2753.
  • Maes, M., B. Leonard, A. Fernandez, M. Kubera, G. Nowak, R. Veerhuis, et al. 2011. (Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: from antioxidants to kinase inhibitors. Prog. Neuropsychopharmacol. Biol. Psychiatry 35:659663.
  • Malaguarnera, M., I. Di Fazio, L. Ferlito, G. Pistone, A. Laurino, E. Vinci, et al. 2000. Increase of serum beta2-microglobulin in patients affected by HCV correlated hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 12:937939.
  • Marksteiner, J., G. Kemmler, E. M. Weiss, G. Knaus, C. Ullrich, S. Mechtcheriakov, et al. 2011. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 32:539540.
  • Martin-Santos, R., C. Diez-Quevedo, P. Castellvi, R. Navines, M. Miquel, H. Masnou, et al. 2008. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Aliment. Pharmacol. Ther. 27:257265.
  • McAfoose, J., and B. T. Baune. 2009. Evidence for a cytokine model of cognitive function. Neurosci. Biobehav. Rev. 33:355366.
  • Meyers, C. A., M. Albitar, and E. Estey. 2005. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 104:788793.
  • Miller, A. H., E. Haroon, C. L. Raison, and J. C. Felger. 2013. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress. Anxiety 30:297306.
  • Mommersteeg, P. M., E. Vermetten, A. Kavelaars, E. Geuze, and C. J. Heijnen. 2008. Hostility is related to clusters of T-cell cytokines and chemokines in healthy men. Psychoneuroendocrinology 33:10411050.
  • Muller, N., M. J. Schwarz, S. Dehning, A. Douhe, A. Cerovecki, B. Goldstein-Muller, et al. 2006. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry 11:680684.
  • Nelligan, J. A., J. M. Loftis, A. M. Matthews, B. L. Zucker, A. M. Linke, and P. Hauser. 2008. Depression comorbidity and antidepressant use in veterans with chronic hepatitis C: results from a retrospective chart review. J. Clin. Psychiatry 69:810816.
  • O'Brien, S. M., P. Scully, P. Fitzgerald, L. V. Scott, and T. G. Dinan. 2007. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J. Psychiatr. Res. 41:326331.
  • O'Bryant, S. E., S. C. Waring, V. Hobson, J. R. Hall, C. B. Moore, T. Bottiglieri, et al. 2010. Decreased C-reactive protein levels in Alzheimer disease. J. Geriatr. Psychiatry Neurol. 23:4953.
  • Owen, B. M., D. Eccleston, I. N. Ferrier, and A. H. Young. 2001. Raised levels of plasma interleukin-1beta in major and postviral depression. Acta Psychiatr. Scand. 103:226228.
  • Patel, A., A. Siegel, and S. S. Zalcman. 2010. Lack of aggression and anxiolytic-like behavior in TNF receptor (TNF-R1 and TNF-R2) deficient mice. Brain Behav. Immun. 24:12761280.
  • Patterson, A. L., B. J. Morasco, B. E. Fuller, D. W. Indest, J. M. Loftis, and P. Hauser. 2011. Screening for depression in patients with hepatitis C using the Beck Depression Inventory-II: do somatic symptoms compromise validity? Gen. Hosp. Psychiatry 33:354362.
  • Pawlak, K., M. Mysliwiec, and D. Pawlak. 2010. Hepatitis C virus seropositivity and TNF superfamily receptors: sCD40, sFas—the new putative determinants of endothelial dysfunction in haemodialysis patients. Thromb. Res. 126:393398.
  • Potter, A., L. Downey, and C. Stough. 2013. Cognitive function in ecstasy naive abstinent drug dependants and MDMA users. Curr. Drug Abuse Rev. 6:7176.
  • Poynard, T., P. Cacoub, V. Ratziu, R. P. Myers, M. H. Dezailles, A. Mercadier, et al. 2002. Fatigue in patients with chronic hepatitis C. J. Viral Hepat. 9:295303.
  • Raison, C. L., R. E. Rutherford, B. J. Woolwine, C. Shuo, P. Schettler, D. F. Drake, et al. 2013. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70:3141.
  • Rethorst, C. D., M. S. Toups, T. L. Greer, P. A. Nakonezny, T. J. Carmody, B. D. Grannemann, et al. 2013. Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol. Psychiatry 18:11191124.
  • Rowan, P. J., R. Al-Jurdi, S. Tavakoli-Tabasi, M. E. Kunik, S. L. Satrom, and H. B. El-Serag. 2005. Physical and psychosocial contributors to quality of life in veterans with hepatitis C not on antiviral therapy. J. Clin. Gastroenterol. 39:731736.
  • Salim, S., G. Chugh, and M. Asghar. 2012. Inflammation in anxiety. Adv. Protein Chem. Struct. Biol. 88:125.
  • Schafers, M., C. Sommer, C. Geis, T. Hagenacker, P. Vandenabeele, and L. S. Sorkin. 2008. Selective stimulation of either tumor necrosis factor receptor differentially induces pain behavior in vivo and ectopic activity in sensory neurons in vitro. Neuroscience 157:414423.
  • Schall, T. J. and K. B. Bacon. 1994. Chemokines, leukocyte trafficking, and inflammation. Curr. Opin. Immunol. 6:865873.
  • Schmidt, H. D., R. C. Shelton, and R. S. Duman. 2011. Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 36:23752394.
  • Schrijvers, E. M., P. J. Koudstaal, A. Hofman, and M. M. Breteler. 2011. Plasma clusterin and the risk of Alzheimer disease. JAMA 305:13221326.
  • Sekine, Y., Y. Ouchi, G. Sugihara, N. Takei, E. Yoshikawa, K. Nakamura, et al. 2008. Methamphetamine causes microglial activation in the brains of human abusers. J. Neurosci. 28:57565761.
  • Sen, S., R. Duman, and G. Sanacora. 2008. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol. Psychiatry 64:527532.
  • Sharma, A., A. Chakraborti, A. Das, R. K. Dhiman, and Y. Chawla. 2009. Elevation of interleukin-18 in chronic hepatitis C: implications for hepatitis C virus pathogenesis. Immunology 128:e514e522.
  • Sheehan, D. V., Y. Lecrubier, K. H. Sheehan, P. Amorim, J. Janavs, E. Weiller, et al. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59:2233.
  • Simen, B. B., C. H. Duman, A. A. Simen, and R. S. Duman. 2006. TNFalpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol. Psychiatry 59:775785.
  • Simon, N. M., K. McNamara, C. W. Chow, R. S. Maser, G. I. Papakostas, M. H. Pollack, et al. 2008. A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur. Neuropsychopharmacol. 18:230233.
  • Slade, G. D., M. S. Conrad, L. Diatchenko, N. U. Rashid, S. Zhong, S. Smith, et al. 2011. Cytokine biomarkers and chronic pain: association of genes, transcription, and circulating proteins with temporomandibular disorders and widespread palpation tenderness. Pain 152:28022812.
  • Sluzewska, A., J. K. Rybakowski, M. Laciak, A. Mackiewicz, M. Sobieska, and K. Wiktorowicz. 1995. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann. N. Y. Acad. Sci. 762:474476.
  • Sousa, G. M., I. S. Oliveira, L. J. Andrade, M. L. Sousa-Atta, R. Paraná, and A. M. Atta. 2012. Serum levels of Th17 associated cytokines in chronic hepatitis C virus infection. Cytokine 60:138142.
  • Tan, G., M. P. Jensen, J. I. Thornby, and B. F. Shanti. 2004. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J. Pain 5:133137.
  • Tawadrous, G. A., A. A. Aziz, D. G. Amin, A. Eldemery, and M. A. Mostafa. 2012. RANTES, TNF-alpha, oxidative stress, and hematological abnormalities in hepatitis C virus infection. J. Investig. Med. 60:878882.
  • Tong, L., R. Balazs, R. Soiampornkul, W. Thangnipon, and C. W. Cotman. 2008. Interleukin-1 beta impairs brain derived neurotrophic factor-induced signal transduction. Neurobiol. Aging 29:13801393.
  • Toro-Nieves, D. M., Y. Rodriguez, M. Plaud, P. Ciborowski, F. Duan, J. Perez Laspiur, et al. 2009. Proteomic analyses of monocyte-derived macrophages infected with human immunodeficiency virus type 1 primary isolates from Hispanic women with and without cognitive impairment. J. Neurovirol. 15:3650.
  • Tyring, S., A. Gottlieb, K. Papp, K. Gordon, C. Leonardi, A. Wang, et al. 2006. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367:2935.
  • Udina, M., P. Castellví, J. Moreno-España, R. Navinés, M. Valdés, X. Forns, et al. 2012. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J. Clin. Psychiatry 73:11281138.
  • Vecchiet, J., K. Falasca, P. Cacciatore, P. Zingariello, M. Dalessandro, M. Marinopiccoli, et al. 2005. Association between plasma interleukin-18 levels and liver injury in chronic hepatitis C virus infection and non-alcoholic fatty liver disease. Ann. Clin. Lab. Sci. 35:415422.
  • Vignali, D. A. 2000. Multiplexed particle-based flow cytometric assays. J. Immunol. Methods 243:243255.
  • Vogel, C., S. Stallforth, and C. Sommer. 2006. Altered pain behavior and regeneration after nerve injury in TNF receptor deficient mice. J. Peripher. Nerv. Syst. 11:294303.
  • Vom Berg, J., S. Prokop, K. R. Miller, J. Obst, R. E. Kälin, I. Lopategui-Cabezas, et al. 2012. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat. Med. 18:18121819.
  • Wang, G. J., N. D. Volkow, L. Chang, E. Miller, M. Sedler, R. Hitzemann, et al. 2004. Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am. J. Psychiatry 161:242248.
  • Warshow, U. M., A. Riva, D. Hegazy, P. H. Thurairajah, E. R. Kaminski, S. Chokshi, et al. 2012. Cytokine profiles in high risk injection drug users suggests innate as opposed to adaptive immunity in apparent resistance to hepatitis C virus infection. J. Viral Hepat. 19:501508.
  • Wechsler, D. 2001. Wechsler Test of Adult Reading (WTAR). Pearson, San Antonio, TX.
  • Whitehead, A. J., S. K. Dobscha, B. J. Morasco, S. Ruimy, C. Bussell, and P. Hauser. 2008. Pain, substance use disorders and opioid analgesic prescription patterns in veterans with hepatitis C. J. Pain Symptom Manage. 36:3945.
  • Wichers, M. C., G. Kenis, C. Leue, G. Koek, G. Robaeys, and M. Maes. 2006. Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol. Psychiatry 60:7779.
  • Wilhelm, C. J., D. Choi, M. Huckans, L. Manthe, and J. M. Loftis. 2013. Adipocytokine signaling is altered in Flinders sensitive line rats, and adiponectin correlates in humans with some symptoms of depression. Pharmacol. Biochem. Behav. 103:643651.
  • Wilkinson, J., M. Radkowski, J. M. Eschbacher, and T. Laskus. 2010. Activation of brain macrophages/microglia cells in hepatitis C infection. Gut 59:13941400.
  • Yaffe, K., A. Kanaya, K. Lindquist, E. M. Simonsick, T. Harris, R. I. Shorr, et al. 2004. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 292:22372242.
  • Yen, D., J. Cheung, H. Scheerens, F. Poulet, T. McClanahan, B. McKenzie, et al. 2006. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116:13101316.
  • Zimmermann, H. W., S. Seidler, N. Gassler, J. Nattermann, T. Luedde, C. Trautwein, et al. 2011. Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis. PLoS ONE 6:e21381.